Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic acid plus interferon alfa for relapsed or refractory neuroblastoma
ACTRN12610000842066Phase 2Terminated
- Sponsor
- Australia & New Zealand Children’s Haematology and Oncology Group
- Start
- Jun 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of valproic acid and interferon alfa in neuroblastoma, sponsored by Australia & New Zealand Children’s Haematology and Oncology Group. Primary endpoint: Objective response rate. Started Jun 2011; status: terminated.
02
Drugs
valproic acidinterferon alfa
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on ACTRN12610000842066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000842066.